ASP3082

Phase 2

Astellas Pharma (ALPMY)

00%

What is LOA?

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

Sep '27

ALPMYPhase 2$27.2B

ASP3082 Phase 2 Est. Readout

ASP3082• Metastatic/Locally Advanced Non-Small-Cell Lung Cancer60

Sep 2027~Estimated

CT.gov

00%

Competitive Landscape

0 competitors in Metastatic/Locally Advanced Non-Small-Cell Lung Cancer

View Full Landscape

Drug Information

Target Indication

Metastatic/Locally Advanced Non-Small-Cell Lung Cancer

Clinical Trial

NCT07483983

Last updated: 9/2/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

ALPMY

Astellas Pharma

Healthcare•North America•NASDAQ

Related Pipeline

OPT-80Phase 3

Clostridium Difficile

VernakalantPhase 3

Atrial Flutter

daclizumabPhase 3

Kidney Transplantation

SetidegrasibPhase 3

Pancreatic Cancer

YM177Phase 3

Post Operative Pain

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts